Evaluation of prophylactic replacement therapy in haemophilia B.
Prophylaxis replacement therapy has been assessed for a period of 12 months in 10 patients with severe haemophilia B showing a high incidence of spontaneous bleeding episodes. Two different schedules of administration of a freeze-dried factor IX concentrate were randomly evaluated: according to scheme A, 7.5 U/kg were administrated biweekly, whereas scheme B was based on the weekly infusion of 15 U/kg. On prophylaxis the frequency of bleeding episodes was significantly reduced (P less than 0.005) when compared with that observed in one-year period preceding the trial. Biweekly infusions were superior to weekly infusion (P less than 0.01), and the benefit appeared to be related to the higher number of days in which measurable levels of factor IX were attained in plasma. Range of motion, which was redeced at the start of the trial in 26 joints, was found to have improved in 23. Favourable changes of the joint radiological picture were observed in 6 cases. Hepatitis and factor IX inhibitors did not develop during the trial period. Side effects were rare and mild.
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D004551:Elbow Joint / Q000000981:diagnostic imaging / Q000503:physiopathology; D005069:Evaluation Studies as Topic; D005164:Factor IX / Q000008:administration & dosage / Q000627:therapeutic use*; D005170:Factor X / Q000627:therapeutic use; D006395:Hemarthrosis / Q000517:prevention & control; D002836:Hemophilia B / Q000097:blood / Q000503:physiopathology / Q000628:therapy*; D006470:Hemorrhage / Q000517:prevention & control*; D006801:Humans; D007719:Knee Joint / Q000000981:diagnostic imaging / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011516:Prothrombin / Q000627:therapeutic use; D011859:Radiography; D013997:Time Factors
D011516:Prothrombin; D005164:Factor IX; D005170:Factor X